Uveal Melanoma

Oncology·MeSH: Uveal Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

15 drugs in development·8 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
KIMMTRAK	Immunocore Holdings plc (IMCR)

Phase 3(1)

Drug	Company
cemiplimab	GH Research PLC (GHRS)

Phase 2(6)

Drug	Company
Darovasertib	IDEAYA Biosciences, Inc. (IDYA)
Infusion of HS-IT101 Injection	Black Diamond Therapeutics, Inc. (BDTX)
Investigator's selection of appropriate chemotherapy regimen	Black Diamond Therapeutics, Inc. (BDTX)
Lymphodepletion Conditioning	Black Diamond Therapeutics, Inc. (BDTX)
Relatlimab	UNITED THERAPEUTICS Corp (UTHR)
RP2	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(2)

Drug	Company
AU-011	Aura Biosciences, Inc. (AURA)
nelitolimod	TriSalus Life Sciences Inc. (TLSI)

Phase 1/Phase 2(3)

Drug	Company
Binimetinib	IDEAYA Biosciences, Inc. (IDYA)
IDE196	IDEAYA Biosciences, Inc. (IDYA)
sd-101	TriSalus Life Sciences Inc. (TLSI)

Phase 2/Phase 3(2)

Drug	Company
Crizotinib	IDEAYA Biosciences, Inc. (IDYA)
Dacarbazine	IDEAYA Biosciences, Inc. (IDYA)

BioSniper tracks 15 drugs in development for Uveal Melanoma across 8 companies.

There are 11 clinical trials targeting Uveal Melanoma tracked by BioSniper.

The estimated prevalence of Uveal Melanoma is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.